439 related articles for article (PubMed ID: 10369403)
1. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract.
Bjarnason I; Thjodleifsson B
Rheumatology (Oxford); 1999 May; 38 Suppl 1():24-32. PubMed ID: 10369403
[TBL] [Abstract][Full Text] [Related]
2. Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions.
Rainsford KD
Rheumatology (Oxford); 1999 May; 38 Suppl 1():4-10. PubMed ID: 10369399
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen.
Bjarnason I; Macpherson A; Rotman H; Schupp J; Hayllar J
Scand J Gastroenterol; 1997 Feb; 32(2):126-30. PubMed ID: 9051872
[TBL] [Abstract][Full Text] [Related]
4. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
[TBL] [Abstract][Full Text] [Related]
6. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
Ballinger A; Smith G
Expert Opin Pharmacother; 2001 Jan; 2(1):31-40. PubMed ID: 11336566
[TBL] [Abstract][Full Text] [Related]
7. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
;
Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
[TBL] [Abstract][Full Text] [Related]
8. Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
Hawkey CJ; Jackson L; Harper SE; Simon TJ; Mortensen E; Lines CR
Aliment Pharmacol Ther; 2001 Jan; 15(1):1-9. PubMed ID: 11136272
[TBL] [Abstract][Full Text] [Related]
9. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
Blain H; Jouzeau JY; Netter P; Jeandel C
Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
Peura DA
Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
Meyer-Kirchrath J; Schrör K
Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
[TBL] [Abstract][Full Text] [Related]
12. New NSAIDs and gastroduodenal damage.
Folco GC
Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
[TBL] [Abstract][Full Text] [Related]
13. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
Bertolini A; Ottani A; Sandrini M
Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
[TBL] [Abstract][Full Text] [Related]
14. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract.
Masferrer JL; Isakson PC; Seibert K
Gastroenterol Clin North Am; 1996 Jun; 25(2):363-72. PubMed ID: 9229578
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal safety of selective COX-2 inhibitors.
Hawkey CJ; Skelly MM
Curr Pharm Des; 2002; 8(12):1077-89. PubMed ID: 11945152
[TBL] [Abstract][Full Text] [Related]
17. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity.
Shah AA; Murray FE; Fitzgerald DJ
Rheumatology (Oxford); 1999 May; 38 Suppl 1():19-23. PubMed ID: 10369402
[TBL] [Abstract][Full Text] [Related]
18. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.
James MW; Hawkey CJ
Br J Clin Pharmacol; 2003 Aug; 56(2):146-55. PubMed ID: 12895187
[TBL] [Abstract][Full Text] [Related]
19. Forthcoming non-steroidal anti-inflammatory drugs: are they really devoid of side effects?
Bjarnason I
Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S27-36. PubMed ID: 10379467
[TBL] [Abstract][Full Text] [Related]
20. Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.
Lehmann FS; Beglinger C
Curr Top Med Chem; 2005; 5(5):449-64. PubMed ID: 15974940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
